The SENS Foundation Research Center is our internal facility for SENS Research. Find out more or make a donation to help our work.
SENS Foundation was founded to develop, promote and ensure widespread access to regenerative medicine solutions to the disabilities and diseases of aging.
Our focus is the Strategies for Engineered Negligible Senescence (SENS) identified by our Chief Science Officer, Dr Aubrey de Grey, and combining direct research efforts with education, affiliation and outreach programs.
You can find more about us, our mission and our history by following the links in the menu above.
Recent news, events and blog posts 
16/07/10 by Michael Rae from Chief Science Officer's Team
Scientists Call for a Biomedical Apollo Project to Avert Global Aging Crisis
Last summer, California-based LifeStar Institute assembled a panel of leaders in the science of aging to ask them the question at the core of their research. How far can the potential of new biomedical therapies to slow, arrest, or even reverse the damage of aging be brought to bear against the challenge of global graying?
09/07/10 by Michael Rae from Chief Science Officer's Team
Functional Lung Tissue-Engineered in Rat Model
Tissue engineering and cell therapy are an essential plank in the Strategies for Engineered Negligible Senescence (SENS) platform of regenerative engineering. These biotechnologies are most obviously central for direct clinical use in repairing and replacing cells and tissues "injured by trauma, damaged by disease or worn by time" (as William Haseltine first defined regenerative
28/06/10 by Michael Rae from Chief Science Officer's Team
Active Aß Immunization Reverses (Some) Neuritic Pathology
A variety of extracellular aggregates accumulate in the aging body, and strong evidence exists for their contribution to age-related morbidity and pathology. This makes them targets for regenerative engineering: the rescue of youthful tissue function through the restoration of structure from such damage. In the case of extracellular aggregates, the most promising biomedical approach is their clearance with targeted immunotherapy.
15/06/10 by Michael Rae from Chief Science Officer's Team
An AID to Faster, More Efficient iPS Derivation?
As anyone following the field will know, the derivation of induced pluripotent (iPS) cells reprogrammed from differentiated somatic cells offers a remarkable promise: the ability to generate donor-specific pluripotent stem cells, without the "ethical" confusion that has so unfortunately retarded the progress of somatic cell nuclear transfer (SCNT) research.
External News
- Singularity Summit 2010 -
- Moral, philosophical questions dog scientists' efforts to repair cells, clear body's garbage' -
- Open Science Summit 2010 -
-
'Artificial life' breakthrough announced by scientists
at BBC
- Aubrey de Grey at How The Light Gets In -
Video
Dr. Aubrey de Grey's talk at TEDMed 2009.
